<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>2018 WHO classification of melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">2018 WHO classification of melanoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">2018 WHO classification of melanoma</div><div class="cntnt"><table cellspacing="0"><colgroup span="12" width="8.3%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1" colspan="4">Low UV radiation exposure/CSD</td> <td class="subtitle1" colspan="2">High UV radiation exposure/CSD</td> <td class="subtitle1" colspan="5">Low to no (or variable/incidental) UV radiation exposure/CSD</td> </tr> <tr> <td><strong>Pathway</strong></td> <td colspan="4"><strong>I</strong></td> <td><strong>II</strong></td> <td><strong>III</strong></td> <td><strong>IV</strong></td> <td><strong>V</strong></td> <td><strong>VI</strong></td> <td><strong>VII</strong></td> <td><strong>VIII</strong></td> </tr> <tr class="divider_bottom"> <td><strong>Endpoint of pathway</strong></td> <td colspan="4"><strong>Low-CSD melanoma/SSM</strong></td> <td><strong>High-CSD melanoma/LMM</strong></td> <td><strong>Desmoplastic melanoma</strong></td> <td><strong>Malignant Spitz tumor/Spitz melanoma</strong></td> <td><strong>Acral melanoma</strong></td> <td><strong>Mucosal melanoma</strong></td> <td><strong>Melanoma in congenital nevus</strong></td> <td><strong>Melanoma in blue nevus</strong></td> </tr> <tr> <td><strong>Benign neoplasms (nevi</strong>)</td> <td colspan="4">Nevus</td> <td> <p>?</p> IMP</td> <td> <p>?</p> IMP</td> <td>Spitz nevus</td> <td> <p>?</p> Acral nevus</td> <td> <p>?</p> Melanosis</td> <td>Congenital nevus</td> <td>Blue nevus</td> </tr> <tr> <td><strong>Intermediate/low-grade dysplasias and melanocytomas</strong></td> <td>Low-grade dysplasia</td> <td>BAP1-inactivated nevus</td> <td>Deep penetrating nevus </td> <td> </td> <td> <p>?</p> IAMP/dysplasia</td> <td> <p>?</p> IAMP/dysplasia</td> <td>Atypical Spitz tumor (melanocytoma)</td> <td>IAMP/ dysplasia</td> <td>Atypical melanosis/dysplasia/IAMPUS</td> <td>Nodule in congenital nevus (melanocytoma)</td> <td>(Atypical) cellular blue nevus (melanocytoma)</td> </tr> <tr> <td><strong>Intermediate/high-grade dysplasias and melanocytomas</strong></td> <td>High-grade dysplasia/MIS</td> <td>BAP1-inactivated melanocytoma/MELTUMP</td> <td>Deep penetrating melanocytoma/MELTUMP</td> <td>Pigmented epithelioid melanocytoma/MELTUMP</td> <td>Lentigo maligna (MIS)</td> <td>MIS</td> <td>STUMP/MELTUMP</td> <td>Acral MIS</td> <td>Mucosal MIS</td> <td>MIS in congenital nevus</td> <td>Atypical cellular blue nevus</td> </tr> <tr> <td><strong>Malignant neoplasms</strong></td> <td>Low-CSD melanoma/SSM (VGP)</td> <td>Melanoma in BAP1-inactivated nevus (rare)</td> <td>Melanoma in deep penetrating nevus (rare)</td> <td>Melanoma in pigmented epithelioid melanocytoma (rare)</td> <td>LMM (VGP)</td> <td>Desmoplastic melanoma</td> <td>Malignant Spitz tumor/Spitz melanoma (tumorigenic)</td> <td>Acral melanoma (VGP)</td> <td>Mucosal lentiginous melanoma (VGP)</td> <td>Melanoma in congenital nevus (tumorigenic)</td> <td>Melanoma in blue nevus (tumorigenic)</td> </tr> <tr> <td rowspan="2"><strong>Common mutations*</strong></td> <td><em><strong>BRAF</strong></em><strong>V600E</strong><sup>¶</sup> or <em><strong>NRAS</strong></em><sup>¶</sup></td> <td> <p><em><strong>BRAF</strong></em><sup>¶</sup> or <em><strong>NRAS</strong></em><sup>¶</sup></p> <p>plus</p> <em><strong>BAP1</strong></em><sup>Δ</sup></td> <td> <p><em><strong>BRAF</strong></em><sup>¶</sup>, <em><strong>MAP2K1</strong></em><sup>¶, </sup>or <em><strong>NRAS</strong></em><sup>¶</sup></p> <p>plus</p> <em><strong>CTNNB1</strong></em><sup>¶</sup> or <em><strong>APC</strong></em><sup>Δ</sup></td> <td><em><strong>BRAF</strong></em><sup>¶</sup> plus <em><strong>PRKAR1A</strong></em><sup>Δ</sup>; or <em><strong>PRKCA</strong></em><sup>¶</sup></td> <td><em><strong>NRAS</strong></em><sup>¶</sup>; <em><strong>BRAF</strong></em> (<strong>non-V600E</strong>)<sup>¶</sup>; <em><strong>KIT</strong></em><sup>¶</sup>; or <em>NF1</em><sup>Δ</sup></td> <td><em><strong>NF1</strong></em><sup>Δ</sup>; <em>ERBB2</em><sup>◊</sup>; <em>MAP2K1</em><sup>◊</sup>; <em>MAP3K1</em><sup>◊</sup>; <em>BRAF</em><sup>◊</sup>; <em>EGFR</em><sup>◊</sup>; <em>MET</em><sup>◊</sup></td> <td><em><strong>HRAS</strong></em><sup>¶</sup>; <em><strong>ALK</strong></em><sup>§</sup>; <em><strong>ROS1</strong></em><sup>§</sup>; <em><strong>RET</strong></em><sup>§</sup>; <em><strong>NTRK1</strong></em><sup>§</sup>; <em><strong>NTRK3</strong></em><sup>§</sup>; <em><strong>BRAF</strong></em><sup>§</sup>; or <em><strong>MET</strong></em><sup>§</sup></td> <td> <p><em><strong>KIT</strong></em><sup>¶</sup>; <em><strong>NRAS</strong></em><sup>¶</sup>; <em><strong>BRAF</strong></em><sup>¶</sup>; <em><strong>HRAS</strong></em><sup>¶</sup>; <em><strong>KRAS</strong></em><sup>¶</sup>; <em><strong>NTRK3</strong></em><sup>§</sup>; <em><strong>ALK</strong></em><sup>§</sup>;</p> <p>or</p> <em><strong>NF1</strong></em><sup>Δ</sup></td> <td><em><strong>KIT</strong></em><sup>¶</sup>, <em><strong>NRAS</strong></em><sup>¶</sup>, <em><strong>KRAS</strong></em><sup>¶</sup>; or <em><strong>BRAF</strong></em><sup>¶</sup></td> <td><em><strong>NRAS</strong></em><sup>¶</sup>; <em><strong>BRAF</strong></em><strong>V600E</strong><sup>¶</sup> (small lesions); or <em><strong>BRAF</strong></em><sup>§</sup></td> <td><em><strong>GNAQ</strong></em><sup>¶</sup>; <em><strong>GNA11</strong></em><sup>¶</sup>; or <em><strong>CYSLTR2</strong></em><sup>¶</sup></td> </tr> <tr> <td><em>TERT</em><sup>‡</sup>; <em>CDKN2A</em><sup>Δ</sup>; <em>TP53</em><sup>Δ</sup>; <em>PTEN</em><sup>Δ</sup></td> <td> </td> <td> </td> <td> </td> <td><em>TERT</em><sup>‡</sup>; <em>CDKN2A</em><sup>Δ</sup>; <em>TP53</em><sup>Δ</sup>; <em>PTEN</em><sup>Δ</sup>; <em>RAC1</em><sup>¶</sup></td> <td><em>TERT</em><sup>‡</sup>; <em>NFKBIE</em><sup>‡</sup>; <em>NRAS</em><sup>¶</sup>; <em>PIK3CA</em><sup>¶</sup>; <em>PTPN11</em><sup>¶</sup></td> <td><em>CDKN2A</em><sup>Δ</sup></td> <td><em>CDKN2A</em><sup>Δ</sup>; <em>TERT</em><sup>‡</sup>; <em>CCND1</em><sup>◊</sup>; <em>GAB2</em><sup>◊</sup></td> <td><em><strong>NF1</strong></em><sup>¶</sup>; <em>CDKN2A</em><sup>Δ</sup>; <em>SF3B1</em><sup>¥</sup>; <em>CCND1</em><sup>◊</sup>; <em>CDK4</em><sup>◊</sup>; <em>MDM2</em><sup>◊</sup></td> <td> </td> <td><em>BAP1</em><sup>Δ</sup>; <em>EIF1AX</em><sup>¶</sup>; <em>SF3B1</em><sup>¶</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">Melanocytoma is a tumorigenic neoplasm of melanocytes that generally has increased cellularity and/or atypia (compared with a common nevus) and an increased (although generally still low) probability of neoplastic progression. Tumorigenic means forming a mass of neoplastic cells.</div><div class="graphic_footnotes">WHO: World Health Organization; UV: ultraviolet; CSD: cumulative sun damage; SSM: superficial spreading melanoma; LMM: lentigo maligna melanoma; IMP: intraepidermal melanocytic proliferation without atypia; IAMP: atypical intraepidermal melanocytic proliferation; IAMPUS: atypical intraepidermal melanocytic proliferation of uncertain significance; MIS: melanoma in situ; MELTUMP: melanocytic tumor of uncertain malignant potential; STUMP: spitzoid tumor of uncertain malignant potential; low/high CSD melanoma: melanoma in skin with a low/high degree of cumulative sun damage; VGP: vertical growth phase (tumorigenic and/or mitogenic melanoma).<br/>* Common mutations in each pathway are listed; mutations already identified in benign or borderline low lesions are shown in <strong>bold</strong>.<br/>¶ Gain-of-function mutation.<br/>Δ Loss-of-function mutation.<br/><font class="lozenge">◊</font> Amplification.<br/>§ Rearrangement.<br/>¥ Change-of-function mutation.<br/>‡ Promoter mutation.</div><div class="graphic_reference">Reproduced with permission from: WHO Classification of Tumours Editorial Board. Skin tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 4th ed.; vol. 11). Available from: <a href="https://tumourclassification.iarc.who.int/" target="_blank">https://tumourclassification.iarc.who.int/</a>. Copyright © David Elder, MBChB.</div><div id="graphicVersion">Graphic 129801 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
